Cargando…
A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma
BACKGROUND: Hematogenous metastasis is essential for the progression of advanced hepatocellular carcinoma (HCC) and can occur even after patients receive multidisciplinary therapies, including immunotherapy and hepatectomy; circulating tumor cells (CTCs) are one of the dominant components of the met...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867854/ https://www.ncbi.nlm.nih.gov/pubmed/36681851 http://dx.doi.org/10.1186/s12951-023-01783-9 |
_version_ | 1784876429444382720 |
---|---|
author | Huang, Xiu-Yan Li, Feng Li, Ting-Ting Zhang, Jun-Tao Shi, Xiang-Jun Huang, Xin-Yu Zhou, Jian Tang, Zhao-You Huang, Zi-Li |
author_facet | Huang, Xiu-Yan Li, Feng Li, Ting-Ting Zhang, Jun-Tao Shi, Xiang-Jun Huang, Xin-Yu Zhou, Jian Tang, Zhao-You Huang, Zi-Li |
author_sort | Huang, Xiu-Yan |
collection | PubMed |
description | BACKGROUND: Hematogenous metastasis is essential for the progression of advanced hepatocellular carcinoma (HCC) and can occur even after patients receive multidisciplinary therapies, including immunotherapy and hepatectomy; circulating tumor cells (CTCs) are one of the dominant components of the metastatic cascade. However, the CTC capture efficiency for HCC is low due to the low sensitivity of the detection method. In this study, epithelial cell adhesion molecule (EpCAM)/vimentin/Glypican-3 (GPC3) antibody-modified lipid magnetic spheres (LMS) were used to capture tumor cells with epithelial phenotype, mesenchymal phenotype and GPC3 phenotype, respectively, in order to capture more CTCs with a more comprehensive phenotype for monitoring tumor metastasis. RESULTS: The novel CTC detection system of Ep-LMS/Vi-LMS/GPC3-LMS was characterized by low toxicity, strong specificity (96.94%), high sensitivity (98.12%) and high capture efficiency (98.64%) in vitro. A sudden increase in CTC counts accompanied by the occurrence of lung metastasis was found in vivo, which was further validated by a clinical study. During follow-up, the rapid increase in CTCs predicted tumor progression in HCC patients. Additionally, genetic testing results showed common genetic alterations in primary tumors, CTCs and metastatic tissues. The proportion of patients predicted to benefit from immunotherapy with the CTC detection method was higher than that for the tissue detection method (76.47% vs. 41.18%, P = 0.037), guiding the application of clinical individualized therapy. CONCLUSIONS: The Ep-LMS/Vi-LMS/GPC3-LMS sequential CTC capture system is convenient and feasible for the clinical prediction of HCC progression. CTCs captured by this system could be used as a suitable alternative to HCC tissue detection in guiding immunotherapy, supporting the clinical application of CTC liquid biopsy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-01783-9. |
format | Online Article Text |
id | pubmed-9867854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98678542023-01-23 A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma Huang, Xiu-Yan Li, Feng Li, Ting-Ting Zhang, Jun-Tao Shi, Xiang-Jun Huang, Xin-Yu Zhou, Jian Tang, Zhao-You Huang, Zi-Li J Nanobiotechnology Research BACKGROUND: Hematogenous metastasis is essential for the progression of advanced hepatocellular carcinoma (HCC) and can occur even after patients receive multidisciplinary therapies, including immunotherapy and hepatectomy; circulating tumor cells (CTCs) are one of the dominant components of the metastatic cascade. However, the CTC capture efficiency for HCC is low due to the low sensitivity of the detection method. In this study, epithelial cell adhesion molecule (EpCAM)/vimentin/Glypican-3 (GPC3) antibody-modified lipid magnetic spheres (LMS) were used to capture tumor cells with epithelial phenotype, mesenchymal phenotype and GPC3 phenotype, respectively, in order to capture more CTCs with a more comprehensive phenotype for monitoring tumor metastasis. RESULTS: The novel CTC detection system of Ep-LMS/Vi-LMS/GPC3-LMS was characterized by low toxicity, strong specificity (96.94%), high sensitivity (98.12%) and high capture efficiency (98.64%) in vitro. A sudden increase in CTC counts accompanied by the occurrence of lung metastasis was found in vivo, which was further validated by a clinical study. During follow-up, the rapid increase in CTCs predicted tumor progression in HCC patients. Additionally, genetic testing results showed common genetic alterations in primary tumors, CTCs and metastatic tissues. The proportion of patients predicted to benefit from immunotherapy with the CTC detection method was higher than that for the tissue detection method (76.47% vs. 41.18%, P = 0.037), guiding the application of clinical individualized therapy. CONCLUSIONS: The Ep-LMS/Vi-LMS/GPC3-LMS sequential CTC capture system is convenient and feasible for the clinical prediction of HCC progression. CTCs captured by this system could be used as a suitable alternative to HCC tissue detection in guiding immunotherapy, supporting the clinical application of CTC liquid biopsy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-01783-9. BioMed Central 2023-01-21 /pmc/articles/PMC9867854/ /pubmed/36681851 http://dx.doi.org/10.1186/s12951-023-01783-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Huang, Xiu-Yan Li, Feng Li, Ting-Ting Zhang, Jun-Tao Shi, Xiang-Jun Huang, Xin-Yu Zhou, Jian Tang, Zhao-You Huang, Zi-Li A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma |
title | A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma |
title_full | A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma |
title_fullStr | A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma |
title_full_unstemmed | A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma |
title_short | A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma |
title_sort | clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867854/ https://www.ncbi.nlm.nih.gov/pubmed/36681851 http://dx.doi.org/10.1186/s12951-023-01783-9 |
work_keys_str_mv | AT huangxiuyan aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT lifeng aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT litingting aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT zhangjuntao aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT shixiangjun aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT huangxinyu aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT zhoujian aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT tangzhaoyou aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT huangzili aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT huangxiuyan clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT lifeng clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT litingting clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT zhangjuntao clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT shixiangjun clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT huangxinyu clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT zhoujian clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT tangzhaoyou clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma AT huangzili clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma |